Miltefosine (Zentaris) was administered orally for 28 days in a dose as close to 2.5 mg per kilogram per day as was practicable. Patients weighing more than 25 kg received 100 mg daily ...

Miltefosine is an antiparasitic, and it’s the most promising treatment that exists for the infection. Before 2013, when the CDC obtained special approval to keep miltefosine within US borders ...

Miltefosine, paromomycin and liposomal amphotericin B are gradually replacing pentavalent antimonials and conventional amphotericin B as the preferred treatments in some regions, ...

The use of oral miltefosine, an antileishmanial agent, was evaluated in 5 patients (all contact lens users) diagnosed with progressive Acanthamoeba keratitis between January 2017 and January 2019.

Nov. 27, 2002 — Miltefosine is a safe and effective oral therapy for the treatment of visceral leishmaniasis, according to results of a randomized, open-label comparison published in the Nov. 28 ...

Called miltefosine, the experimental drug is not approved for use in the United States, but has been prescribed on a case by case basis to treat a parasitic infection called leishmaniasis, ...

Miltefosine, a broad-spectrum antimicrobial phospholipid drug originally developed as an anticancer agent, received FDA approval for the parasitic disease leishmaniasis in 2013, ...

Brain-eating amoeba attacks Texas teen 01:18. Doctors treating Riley obtained the drug, miltefosine, which is normally used to treat another parasitic disease found in the tropics called ...

Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. It is already approved to treat visceral, mucosal ...

It's called Miltefosine, and it has been effective against similar microbes. Although this drug isn't approved for general use, the Centers for Disease Control and Prevention obtained special ...

To the Editor: The study by Sundar et al. (Nov. 28 issue)1 regarding oral miltefosine for the treatment of Indian visceral leishmaniasis is very promising. However, the reason for excluding from t ...